Products for Research Use Only

Bifendate

CAT: 0804-HY-W018791-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-W018791-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bifendate (DDB), extracted from Schisandrae chinensis, is an orally active anti-HBV agent against chronic hepatitis B. Bifendate inhibits ATG5-dependent autophagy and attenuates oleic acid-induced lipid accumulation with anti-oxidant properties in vitro. Bifendate can decrease alanine transaminase (ALT) level in mice. Bifendate attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Bifendate potently increases the activity of cytochrome proteins (CYPs) and reverse P-gp-mediated multi-drug resistance (MDR) [1][2][3][4][5][6].
CAS Number
73536-69-3
Product Name Alternative
DDB
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Atg8/LC3; Autophagy; Cytochrome P450; HBV; p62; P-glycoprotein
Type
Reference compound
Related Pathways
Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Cancer; Infection; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/bifendate.html
Purity
99.92
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C2=C(OC)C1=C(OCO1)C(=C2C(OC)=O)C3=C(C=C(OC)C4=C3OCO4)C(OC)=O
Molecular Formula
C20H18O10
Molecular Weight
418.35
Precautions
H302, H315, H319, H335
References & Citations
[1]Cui S, et al. [Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study]. Zhonghua Yi Xue Za Zhi. 2002 Apr 25;82 (8) :538-40.|[2]Yuan W, et al. Bifendate inhibits autophagy at multiple steps and attenuates oleic acid-induced lipid accumulation. Biochem Biophys Res Commun. 2022 Nov 26;631:115-123. |[3]Xiao Y, et al. Self-emulsifying bifendate pellets: preparation, characterization and oral bioavailability in rats. Drug Dev Ind Pharm. 2013 May;39 (5) :724-32.|[4]Pan SY, et al. Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol. 2006 Dec 15;552 (1-3) :170-5. |[5]Yue S, et al. Hepatoprotective Effect of Apigenin Against Liver Injury via the Non-canonical NF-κB Pathway In Vivo and In Vitro. Inflammation. 2020 Oct;43 (5) :1634-1648.|[6]Zeng Y, et al. Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacol Sin. 2009 Apr;30 (4) :478-84.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched